Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1
Yaoyun Niu, Yuehui Zhang, Wanqiu Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 25

Showing 25 citing articles:

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway
Wanqiu Zhang, Jinghua Lu, Yangyang Wang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 858-858
Open Access | Times Cited: 58
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of Canagliflozin against methotrexate-induced cognitive impairment
Lobna H. Khedr, Rania M. Rahmo, Omar Mohsen Eldemerdash, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111709-111709
Closed Access | Times Cited: 10
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus
Xiaoxiao Wu, Junhao Yang, Juanjie Wu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116261-116261
Open Access | Times Cited: 8
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications
Abhishek Satheesan, Janardanan Kumar, K.V. Leela, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 2753-2779
Closed Access | Times Cited: 6
Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways
Hanan S. Althagafy, Fares E.M. Ali, Emad H. M. Hassanein, et al.
European Journal of Pharmacology (2023) Vol. 960, pp. 176166-176166
Closed Access | Times Cited: 15
Canagliflozin Mitigated Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer’s Disease in Mice: Role of AMPK/SIRT-1 Signaling Pathway in Modulating Neuroinflammation
Sara M Khamies, Mohammed F. El-Yamany, Sherehan M. Ibrahim
Journal of Neuroimmune Pharmacology (2024) Vol. 19, Iss. 1
Closed Access | Times Cited: 5
p300 upregulates Ikur in atrial cardiomyocytes through activating NLRP3 inflammasome in hypertension
Long Zeng, Panyue Liu, Fang Rao, et al.
Chinese Medical Journal (2025)
Open Access
Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, et al.
Frontiers in Veterinary Science (2025) Vol. 12
Open Access
Treatment Progress of SGLT2 Inhibitors in Anemia of CKD
润智 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 671-677
Closed Access
Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1
Kelly J. Peyton, Ghazaleh Behnammanesh, Giovanna L. Durante, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8777-8777
Open Access | Times Cited: 15
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Canagliflozin inhibits inflammasome activation in diabetic endothelial cells – Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells
Xiaoling Li, Raphaela P. Kerindongo, Benedikt Preckel, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 159, pp. 114228-114228
Open Access | Times Cited: 8
Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway
Wenhui Hao, Wenjie Shan, Fang Wan, et al.
Antioxidants (2023) Vol. 12, Iss. 4, pp. 838-838
Open Access | Times Cited: 7
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
Hong Liu, Weidong Chen, Sheng Wan, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 12, pp. 10325-10337
Closed Access | Times Cited: 7
Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis
Ke Hu, Jiang Pin, Jiaxin Hu, et al.
Journal of Bioenergetics and Biomembranes (2024) Vol. 56, Iss. 4, pp. 361-371
Open Access | Times Cited: 2
AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats
Wafaa A. Hewedy, Shaymaa A. Abdulmalek, Doaa A. Ghareeb, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 2, pp. 873-888
Open Access | Times Cited: 5
Bif‑1 inhibits activation of inflammasome through autophagy regulatory mechanism
Yuehui Zhang, Su Wenhui, Yaoyun Niu, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 4
Open Access | Times Cited: 1
Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
LiGang Huang, Rong Hu, HaiTao Zou
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Targeting the Sirtuin–1/PPAR–Gamma Axis, RAGE/HMGB1/NF-κB Signaling, and the Mitochondrial Functions by Canagliflozin Augments the Protective Effects of Levodopa/Carbidopa in Rotenone-Induced Parkinson’s Disease
M.H.R. El-Kady, Ahmed M. Kabel, Lamees M. Dawood, et al.
Medicina (2024) Vol. 60, Iss. 10, pp. 1682-1682
Open Access | Times Cited: 1
Antibacterial Activity and Mechanism of Canagliflozin against Methicillin-Resistant Staphylococcus aureus
Siyao Gu, Bing Fan, Fang Wan, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5668-5668
Open Access | Times Cited: 3
Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome
Laura Pérez‐Martínez, Lourdes Romero, Eva M. Verdugo‐Sivianes, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0286201-e0286201
Open Access
Potential Reno-protective Influence of Canagliflozin in Male Albino Rats with Metabolic Syndrome
Hanan Shamardl, Sawsan A. Sadek, Amany Ahmed
Fayoum University Medical Journal/Fayoum University Medical Journal (2023) Vol. 12, Iss. 2, pp. 73-83
Open Access
Page 1

Scroll to top